U.S. Markets open in 8 hrs 3 mins
  • S&P Futures

    4,163.00
    -20.50 (-0.49%)
     
  • Dow Futures

    34,580.00
    -88.00 (-0.25%)
     
  • Nasdaq Futures

    13,244.75
    -112.00 (-0.84%)
     
  • Russell 2000 Futures

    2,188.90
    -20.70 (-0.94%)
     
  • Crude Oil

    64.32
    -0.60 (-0.92%)
     
  • Gold

    1,836.90
    -0.70 (-0.04%)
     
  • Silver

    27.28
    -0.19 (-0.71%)
     
  • EUR/USD

    1.2149
    +0.0015 (+0.1215%)
     
  • 10-Yr Bond

    1.6020
    0.0000 (0.00%)
     
  • Vix

    19.66
    +2.97 (+17.80%)
     
  • GBP/USD

    1.4128
    +0.0007 (+0.0480%)
     
  • USD/JPY

    108.8330
    -0.0080 (-0.0074%)
     
  • BTC-USD

    55,205.23
    -3,750.40 (-6.36%)
     
  • CMC Crypto 200

    1,459.05
    -102.25 (-6.55%)
     
  • FTSE 100

    7,123.68
    -6.03 (-0.08%)
     
  • Nikkei 225

    28,599.01
    -919.29 (-3.11%)
     

Recap: Perrigo Q2 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Perrigo (NYSE:PRGO) rose 0.9% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share rose 19.77% over the past year to $1.03, which beat the estimate of $0.88.

Revenue of $1,219,000,000 rose by 8.16% from the same period last year, which missed the estimate of $1,240,000,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Aug 05, 2020

View more earnings on PRGO

Time: 09:00 AM

ET Webcast URL: https://investor.perrigo.com/events-webcasts

Technicals

Company's 52-week high was at $63.86

52-week low: $40.01

Price action over last quarter: Up 5.58%

Company Description

Perrigo is the leading provider of over-the-counter generic drugs with over 100 global locations. The company was formed in 1887 as a packager of home remedies and has grown with the migration of prescriptions switching to over the counter and later with strategic acquisitions. The company has a portfolio of more than 3,000 product formulations and 14,000 stock-keeping units. Most of its manufacturing and customer base reside in North America. With the most recent management change, the company announced a narrower focus on consumer wellness in conjunction with the divestiture of animal health, acquisition of Ranir Global Holdings, and plans to sell or spin off the prescription business.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.